Chen Wu , Xiang Li , Shiyang Liu , Litong Yao , Tianyi He , Yusong Wang , Haoran Dong , Shuyi Niu , Mozhi Wang , Yingying Xu
{"title":"从少转移角度看新发转移性乳腺癌的原发肿瘤切除术：系统回顾和荟萃分析","authors":"Chen Wu , Xiang Li , Shiyang Liu , Litong Yao , Tianyi He , Yusong Wang , Haoran Dong , Shuyi Niu , Mozhi Wang , Yingying Xu","doi":"10.1016/j.isci.2024.111224","DOIUrl":null,"url":null,"abstract":"<div><div>Whether patients with <em>de novo</em> metastatic breast cancer (<em>de novo</em> MBC) benefit from primary tumor resection (PTR) is controversial, and the efficacy of treatment of primary tumor in patients with oligometastases is uncertain. A comprehensive search was conducted for studies published from January 1, 2008 to January 1, 2024 that compared PTR with no PTR for <em>de novo</em> MBC that quantified the extent of metastasis. Ten studies and 83,559 patients with <em>de novo</em> MBC were included. A meta-analysis showed a significant improvement in overall survival after PTR compared with no PTR (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.53–0.67; <em>p</em> < 0.00001). Similar results were seen in patients with 1 metastatic organ, ≤2 metastatic organs, and ≤3 metastatic organs. Oligometastatic patients are expected to be a beneficial subgroup for PTR in patients with MBC, especially when metastasis occurs in only one organ.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"27 12","pages":"Article 111224"},"PeriodicalIF":4.6000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Primary tumor resection in de novo metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis\",\"authors\":\"Chen Wu , Xiang Li , Shiyang Liu , Litong Yao , Tianyi He , Yusong Wang , Haoran Dong , Shuyi Niu , Mozhi Wang , Yingying Xu\",\"doi\":\"10.1016/j.isci.2024.111224\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Whether patients with <em>de novo</em> metastatic breast cancer (<em>de novo</em> MBC) benefit from primary tumor resection (PTR) is controversial, and the efficacy of treatment of primary tumor in patients with oligometastases is uncertain. A comprehensive search was conducted for studies published from January 1, 2008 to January 1, 2024 that compared PTR with no PTR for <em>de novo</em> MBC that quantified the extent of metastasis. Ten studies and 83,559 patients with <em>de novo</em> MBC were included. A meta-analysis showed a significant improvement in overall survival after PTR compared with no PTR (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.53–0.67; <em>p</em> < 0.00001). Similar results were seen in patients with 1 metastatic organ, ≤2 metastatic organs, and ≤3 metastatic organs. Oligometastatic patients are expected to be a beneficial subgroup for PTR in patients with MBC, especially when metastasis occurs in only one organ.</div></div>\",\"PeriodicalId\":342,\"journal\":{\"name\":\"iScience\",\"volume\":\"27 12\",\"pages\":\"Article 111224\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iScience\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589004224024490\",\"RegionNum\":2,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004224024490","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
新发转移性乳腺癌（de novo metastatic breast cancer，de novo MBC）患者是否能从原发肿瘤切除术（PTR）中获益尚存争议，而对寡转移患者原发肿瘤的治疗效果也不确定。我们全面检索了2008年1月1日至2024年1月1日期间发表的研究，这些研究比较了对新发MBC进行原发肿瘤切除与不进行原发肿瘤切除的情况，并对转移范围进行了量化。共纳入了 10 项研究和 83,559 例新发 MBC 患者。一项荟萃分析显示，与不进行 PTR 相比，进行 PTR 后总生存率显著提高（危险比 [HR]，0.60；95% 置信区间 [CI]，0.53-0.67；P < 0.00001）。有 1 个转移器官、≤2 个转移器官和≤3 个转移器官的患者的结果相似。少转移患者有望成为PTR对MBC患者有益的亚组，尤其是当转移仅发生在一个器官时。
Primary tumor resection in de novo metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis
Whether patients with de novo metastatic breast cancer (de novo MBC) benefit from primary tumor resection (PTR) is controversial, and the efficacy of treatment of primary tumor in patients with oligometastases is uncertain. A comprehensive search was conducted for studies published from January 1, 2008 to January 1, 2024 that compared PTR with no PTR for de novo MBC that quantified the extent of metastasis. Ten studies and 83,559 patients with de novo MBC were included. A meta-analysis showed a significant improvement in overall survival after PTR compared with no PTR (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.53–0.67; p < 0.00001). Similar results were seen in patients with 1 metastatic organ, ≤2 metastatic organs, and ≤3 metastatic organs. Oligometastatic patients are expected to be a beneficial subgroup for PTR in patients with MBC, especially when metastasis occurs in only one organ.
期刊介绍：
Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results.
We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
